Dermatology and therapy · 2026
Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stander Sonja, Zeidler Claudia, Msihid Jerome, Makhija Melanie, Bansal Ashish, Wiggins Simmi, Zahn Joseph, Thomas Ryan B, Bahloul Donia
Аннотация
INTRODUCTION: Prurigo nodularis (PN) is a dermatological condition characterized by intensely itchy nodules. The Prurigo Activity and Severity (PAS) assessment tool is a clinician-reported questionnaire used in the phase 3 dupilumab trials.
METHODS: This post hoc analysis of pooled data from the PRIME (NCT04183335) and PRIME2 (NCT04202679) phase 3 clinical trials evaluated the effect of dupilumab on PAS score using a scoring algorithm based on items 2 (number of pruriginous lesions), 5a (percentage of pruriginous lesions with excoriations/crusts), and 5b (percentage of healed lesions). The mean change from baseline in PAS score (range: 0-11, with higher scores indicating greater severity) and the responder rates based on a clinically meaningful threshold (3.0 points) were compared between groups at week 24. The proportion of patients achieving ≤ 25% lesions with excoriations/crusts (PAS 5a) and the proportion of patients with ≥ 75% healed lesions (PAS 5b) were also analyzed to put the responder analyses in perspective.
RESULTS: Dupilumab showed significantly greater reduction versus placebo in mean change in PAS score from baseline to week 24 (absolute least squares [LS] mean difference: -2.7, 95% confidence interval [CI] [-3.3, -2.1]; P < 0.0001). PAS responder rate was significantly higher with dupilumab versus placebo (69.3% versus 27.2%, P < 0.0001). At week 24, significantly higher proportions of dupilumab-treated patients compared with placebo achieved both ≤ 25% lesions with excoriations/crusts (PAS 5a; 71.2% versus 30.4%; odds ratio [OR]: 6.2 [3.6, 10.8], P < 0.0001) and ≥ 75% healed lesions (PAS 5b; 56.2% versus 18.4%; OR: 5.9 [3.3, 10.4], P < 0.0001).
CONCLUSIONS: This evidence shows that the effect of dupilumab on PAS score is significant and clinically meaningful to patients.
TRIAL REGISTRATION: ClinicalTrials. gov identifier; PRIME NCT04183335, PRIME2 NCT04202679.
METHODS: This post hoc analysis of pooled data from the PRIME (NCT04183335) and PRIME2 (NCT04202679) phase 3 clinical trials evaluated the effect of dupilumab on PAS score using a scoring algorithm based on items 2 (number of pruriginous lesions), 5a (percentage of pruriginous lesions with excoriations/crusts), and 5b (percentage of healed lesions). The mean change from baseline in PAS score (range: 0-11, with higher scores indicating greater severity) and the responder rates based on a clinically meaningful threshold (3.0 points) were compared between groups at week 24. The proportion of patients achieving ≤ 25% lesions with excoriations/crusts (PAS 5a) and the proportion of patients with ≥ 75% healed lesions (PAS 5b) were also analyzed to put the responder analyses in perspective.
RESULTS: Dupilumab showed significantly greater reduction versus placebo in mean change in PAS score from baseline to week 24 (absolute least squares [LS] mean difference: -2.7, 95% confidence interval [CI] [-3.3, -2.1]; P < 0.0001). PAS responder rate was significantly higher with dupilumab versus placebo (69.3% versus 27.2%, P < 0.0001). At week 24, significantly higher proportions of dupilumab-treated patients compared with placebo achieved both ≤ 25% lesions with excoriations/crusts (PAS 5a; 71.2% versus 30.4%; odds ratio [OR]: 6.2 [3.6, 10.8], P < 0.0001) and ≥ 75% healed lesions (PAS 5b; 56.2% versus 18.4%; OR: 5.9 [3.3, 10.4], P < 0.0001).
CONCLUSIONS: This evidence shows that the effect of dupilumab on PAS score is significant and clinically meaningful to patients.
TRIAL REGISTRATION: ClinicalTrials. gov identifier; PRIME NCT04183335, PRIME2 NCT04202679.